A client alert by Milwaukee partner Robyn Shapiro and associate Julie Rusczek was published in BNA’s Pharmaceutical Law & Industry Report.

The article, “Life Sciences Research: Preparing for CMS's Final ‘Sunshine’ Rule,” highlights significant implications of the Centers for Medicare and Medicaid Services’ (CMS) Final ‘Sunshine’ Rule in the research context.

The Final Rule implements Section 6002 of the Patient Protection and Affordable Care Act (PPACA). The act’s disclosure requirements are intended to reduce the risk that inappropriate financial incentives will interfere with medical judgment and patient care.

Robyn and Julie’s discussion highlights significant implications of the Final Rule for entities engaged in research (including circumstances under which delayed website publication of research payments is allowed), identifies questions that remain unanswered, and recommends actions for life sciences companies to prepare for the changes ahead.

To read the entire article, click below. A subscription may be required to view this publication.
Source: BNA’s Pharmaceutical Law & Industry Report
Leave Drinker Biddle to Learn More